Annual Financial Results

Fredun Pharmaceuticals delivers strong FY26 performance with 40% revenue growth and 72% EBITDA surge

NSE

not listed

BSE

539730

Fredun Pharmaceuticals Limited reported robust FY26 audited financial results with strong operational momentum across pharmaceuticals, nutraceuticals, cosmetics, and animal healthcare segments. FY26 revenue rose 40% YoY to ₹639.12 crore, while EBITDA increased 72% YoY to ₹94.79 crore and PAT surged nearly 60% YoY to ₹33.21 crore, supported by margin expansion, operating leverage, and diversified business growth.

PRICE-SENSITIVE TRIGGER

Event: FY26 audited financial results announcement

Type: Annual Financial Results

Impact: Positive

Immediate Effect: Strong earnings growth, expanding profitability margins, bonus share recommendation, and strategic expansion initiatives strengthen investor confidence and reinforce long-term growth visibility.

Key Metrics:

FY26 Revenue: ₹639.12 crore vs ₹456.27 crore in FY25; up 40.08% YoY
FY26 EBITDA: ₹94.79 crore vs ₹55.10 crore in FY25; up 72.05% YoY
FY26 EBITDA Margin: 14.83% vs 12.08% in FY25; expansion of 276 bps
FY26 Net Profit: ₹33.21 crore vs ₹20.81 crore in FY25; up 59.59% YoY
FY26 Net Profit Margin: 5.20% vs 4.56% in FY25; expansion of 64 bps
Q4 FY26 Revenue: ₹213.05 crore vs ₹167.41 crore in Q4 FY25; up 27.27% YoY
Q4 FY26 EBITDA: ₹29.13 crore vs ₹17.44 crore in Q4 FY25; up 67.05% YoY
Q4 FY26 PAT: ₹11.07 crore vs ₹7.07 crore in Q4 FY25; up 56.47% YoY
Dividend Recommendation: ₹0.70 per equity share recommended by the Board
Bonus Issue Recommendation: Bonus shares proposed in the ratio of 2:1
Credit Rating Upgrade: Upgraded to IVR BBB+ (Stable) from IVR BBB (Stable) covering bank facilities of ~₹156.17 crore

Highlight:

Label: FY26 Profitability Growth
Value: EBITDA surged 72% YoY while PAT increased ~60% YoY with broad-based margin expansion

What Happened ?

Fredun Pharmaceuticals Limited announced its audited Q4 FY26 and FY26 financial results, reporting strong growth across key profitability metrics driven by operating leverage, cost discipline, and improving business diversification.

The company delivered 40% YoY revenue growth in FY26 while EBITDA and PAT outpaced revenue growth significantly, indicating improvement in business quality and margin profile.

Alongside financial performance, the company announced several strategic initiatives including the launch of premium hormone therapeutics products, rollout of the DAULCÉL longevity platform, manufacturing expansion at Palghar, and a credit rating upgrade.

The Board also recommended a dividend of ₹0.70 per share and proposed a 2:1 bonus share issuance subject to shareholder approval.

Key Details

Operational Expansion & Strategic Developments:

The company launched a premium hormone therapeutics range focused on longevity, hormone health, and performance care.
Management introduced a doctor-led and evidence-backed digital-first patient engagement model to strengthen healthcare positioning.
Fredun announced the launch of “DAULCÉL,” a premium NAD+ based wellness and longevity platform targeting preventive healthcare and healthy aging markets.
The company is expanding into lifestyle wellness and preventive healthcare categories to diversify future revenue streams.
Expansion of the fifth manufacturing facility at Palghar will add 40,000 sq. ft. manufacturing capacity.
The new facility is expected to become operational by October 2026 and will support veterinary, nutraceutical, and pharmaceutical formulations manufacturing.
An additional 50,000 sq. ft. expansion is already planned as part of the next growth phase.
Infomerics upgraded the company’s credit rating to IVR BBB+ (Stable), strengthening institutional credibility and banking confidence.
Management highlighted positive cash flow generation and improving financial health during FY26.

Note:

The company’s FY26 growth reflects a combination of operational scale-up, diversified healthcare exposure, margin expansion, and strategic investment into higher-value wellness and specialty healthcare segments.

Risk Analysis

Summary:

Despite strong financial momentum, the company faces execution and scaling risks associated with expansion into premium wellness categories, manufacturing scale-up, and sustaining margin improvements amid competitive pharmaceutical markets.

Key Risks:

Expansion into premium hormone therapy and longevity wellness segments may require sustained marketing and brand investments.
Manufacturing facility execution delays at Palghar could impact future capacity utilization targets.
Margin expansion sustainability remains dependent on operating leverage and cost management.
Pharmaceutical and nutraceutical sectors remain exposed to regulatory approvals, pricing pressure, and export market volatility.
Bonus issue and future expansion plans may increase operational complexity and working capital requirements.
Growth in newer wellness categories may take time to materially contribute to earnings.

Worst Case Scenario:

If demand momentum weakens, expansion projects are delayed, or operating costs rise sharply, profitability growth could moderate despite strong topline expansion.

Risk Level: Medium

Company Commentary

Managing Director Fredun Medhora stated that FY26 reflects steady progress in building a diversified and resilient business with growth visible across multiple segments.
Management highlighted increasing traction in nutraceuticals, cosmetics, and pet care businesses alongside strength in generics.
The company stated that launch of hormone therapy products and the DAULCÉL platform marks entry into specialized wellness and preventive healthcare segments.
Management emphasized that the Palghar facility expansion and improved credit profile strengthen capacity and financial flexibility for future growth.
The company reiterated its focus on gradually increasing the share of differentiated and higher-value products in its portfolio.
Management expressed confidence in sustaining operational momentum and delivering consistent long-term growth.

Official Exchange Filing: Fredun Pharmaceuticals Limited